In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

CNS therapeutics firm Sage nets $549mm in FOPO

Executive Summary

CNS-focused Sage Therapeutics Inc. netted $549mm in a follow-on offering of 3.5mm shares at $164. The company will use the proceeds to support the potential launch of Phase III brexanolone (SAGE547) in postpartum depression (PPD), for which an NDA filing is expected in 2H 2018; to continue development of GABAA receptor modulator SAGE217 in major depressive disorder, PPD, Parkinson’s disease, and PPD (Phase II), insomnia (Phase I), bipolar disorder (preclinical), and other CNS indications; and to further other pipeline programs, including SAGE718 (in Phase I for CNS diseases related to NMDA receptor hypofunction) and SAGE324 (in preclinical studies for epileptiform disorders and essential tremor). Sage will also put some of the proceeds toward growing its commercial and manufacturing capabilities.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies

Advertisement
UsernamePublicRestriction

Register